Corvex Management LP Decreased Holding in Medicines Co (MDCO) by $19.73 Million

March 14, 2018 - By Kurt Siggers

Investors sentiment decreased to 0.78 in Q3 2017. Its down 0.44, from 1.22 in 2017Q2. It fall, as 32 investors sold MDCO shares while 64 reduced holdings. 19 funds opened positions while 56 raised stakes. 85.15 million shares or 1.36% less from 86.33 million shares in 2017Q2 were reported. Rhumbline Advisers accumulated 142,270 shares. Renaissance Ltd Com holds 0.01% or 129,029 shares in its portfolio. The New York-based Citigroup Inc has invested 0% in The Medicines Company (NASDAQ:MDCO). Intll Grp Inc has invested 0.01% in The Medicines Company (NASDAQ:MDCO). Nationwide Fund Advisors holds 0.01% of its portfolio in The Medicines Company (NASDAQ:MDCO) for 68,238 shares. Cim Invest Mangement holds 0.08% of its portfolio in The Medicines Company (NASDAQ:MDCO) for 6,157 shares. Focused Wealth Management has invested 0.07% in The Medicines Company (NASDAQ:MDCO). Glenmede Na holds 0% or 183 shares. Strs Ohio has invested 0% in The Medicines Company (NASDAQ:MDCO). 46,231 were accumulated by Metropolitan Life Ny. 75,403 are held by Millennium Ltd Liability Corporation. Federated Inc Pa reported 0.02% stake. Wells Fargo & Comm Mn, California-based fund reported 123,384 shares. Riverhead Mgmt Ltd has 8,006 shares. Whittier Trust Commerce has 26,068 shares.

Since December 7, 2017, it had 1 buy, and 1 sale for $1.60 million activity. ESHELMAN FREDRIC N also bought $5.31 million worth of The Medicines Company (NASDAQ:MDCO) on Thursday, December 7.

Keith Meister decreased its stake in Medicines Co (MDCO) by 18.11% based on its latest 2017Q3 regulatory filing with the SEC. Corvex Management Lp sold 533,227 shares as the company’s stock declined 20.30% while stock markets rallied. The hedge fund run by Keith Meister held 2.41 million shares of the major pharmaceuticals company at the end of 2017Q3, valued at $89.30M, down from 2.94M at the end of the previous reported quarter. Corvex Management Lp who had been investing in Medicines Co for a number of months, seems to be less bullish one the $2.52 billion market cap company. The stock decreased 0.98% or $0.34 during the last trading session, reaching $34.43. About 658,255 shares traded. The Medicines Company (NASDAQ:MDCO) has risen 16.70% since March 14, 2017 and is uptrending. It has by 0.00% the S&P500.

Analysts await The Medicines Company (NASDAQ:MDCO) to report earnings on April, 25. They expect $-0.75 earnings per share, up 47.92 % or $0.69 from last year’s $-1.44 per share. After $-2.19 actual earnings per share reported by The Medicines Company for the previous quarter, Wall Street now forecasts -65.75 % EPS growth.

More notable recent The Medicines Company (NASDAQ:MDCO) news were published by: which released: “The Medicines Company Reports Fourth-Quarter and Full-Year 2017 Business and …” on February 21, 2018, also with their article: “The Medicines Company to Participate in the Cowen 38” published on March 08, 2018, published: “The Medicines Company: The Upcoming ODYSSEY Trial Results Could Make It A More …” on March 08, 2018. More interesting news about The Medicines Company (NASDAQ:MDCO) were released by: and their article: “The Medicines Company Reaches Enrollment Target for ORION-10 Ahead of Schedule” published on March 08, 2018 as well as‘s news article titled: “Activist Alex Denner to gain board control at Medicines Co.” with publication date: March 01, 2018.

The Medicines Company (NASDAQ:MDCO) Ratings Coverage

Among 11 analysts covering The Medicines Co (NASDAQ:MDCO), 10 have Buy rating, 0 Sell and 1 Hold. Therefore 91% are positive. The Medicines Co had 36 analyst reports since August 28, 2015 according to SRatingsIntel. RBC Capital Markets maintained The Medicines Company (NASDAQ:MDCO) rating on Monday, November 16. RBC Capital Markets has “Outperform” rating and $48 target. The rating was maintained by RBC Capital Markets on Monday, August 31 with “Outperform”. Guggenheim initiated the stock with “Buy” rating in Monday, October 23 report. Cowen & Co maintained it with “Buy” rating and $5400 target in Wednesday, August 9 report. As per Thursday, February 22, the company rating was maintained by Oppenheimer. On Monday, August 31 the stock rating was maintained by Oppenheimer with “Market Perform”. The rating was initiated by H.C. Wainwright with “Buy” on Monday, December 5. On Tuesday, July 25 the stock rating was maintained by H.C. Wainwright with “Buy”. The firm has “Buy” rating by JP Morgan given on Saturday, August 29. The company was upgraded on Wednesday, November 29 by Oppenheimer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.